MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS

测量静息记忆 CD4 细胞中复制能力的 HIV-1 清除率

• 批准号: 7719441
• 负责人: THOMAS A CAMPBELL
• 金额: $ 0.1万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719441
• 关键词: Blood; Cell Count; Cells; Clinical; Computer Retrieval of Information on Scientific Projects Database; Count; Dose; Funding; Future; Fuzeon; Gilead brand of tenofovir disoproxil fumarate; Grant; HIV; HIV therapy; Institution; Lamivudine; Measures; Memory; Persons; Pharmaceutical Preparations; Purpose; Research; Research Personnel; Resources; Rest; Ritonavir; Safety; Saquinavir; Saquinavir Mesylate; Schedule; Source; T-20; Tenofovir; Testing; Time; United States Food and Drug Administration; United States National Institutes of Health; Virus; base; dosage; epivir; experience; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies have shown that HIV can survive in cells for long periods of time even while a person is on HIV therapy. The HIV virus can survive in these cells for a very long time in a "resting" or "latent" state. The virus in these cells is not active but could become active in the future. The main purpose of this research study is to count the number of cells with HIV that are resting, or latent, in the blood of people taking a new combination of HIV drugs. The latent reservoir test has not been proven to be of clinical benefit. The combination of HIV drugs includes an investigational HIV drug called T-20 (enfuvirtide, or Fuzeon), which is not approved by the U. S. Food and Drug Administration (FDA). This study will look at the safety of T-20 when it is given with four FDA-approved HIV drugs. These other drugs are tenofovir (TDF, or Viread), lamivudine (3TC, or Epivir), saquinavir (SQV, or Invirase), and ritonavir (RTV, or Norvir). The dosage (dose and schedule) of ritonavir and saquinavir in this study were chosen based on experience in the treatment of people with HIV, but are different than the FDA-approved dosages.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 研究表明，即使一个人正在接受艾滋病毒治疗，艾滋病毒也可以在细胞中存活很长时间。 HIV病毒可以在这些细胞中以“休息”或“潜伏”状态存活很长时间。 这些细胞中的病毒不活跃，但将来可能会变得活跃。 这项研究的主要目的是计算服用新的 HIV 药物组合的人血液中静止或潜伏的 HIV 细胞数量。 潜伏储库试验尚未被证明具有临床益处。 HIV药物组合包括一种名为T-20（enfuvirtide或Fuzeon）的研究性HIV药物，该药物未经美国食品和药物管理局（FDA）批准。 这项研究将考察 T-20 与 FDA 批准的四种 HIV 药物联合使用时的安全性。 这些其他药物包括替诺福韦（TDF，或 Viread）、拉米夫定（3TC，或 Epivir）、沙奎那韦（SQV，或 Invirase）和利托那韦（RTV，或 Norvir）。 本研究中利托那韦和沙奎那韦的剂量（剂量和时间表）是根据治疗艾滋病毒感染者的经验选择的，但与 FDA 批准的剂量不同。